Top 10 stories of 2020 on Ophthalmology Times®
January 16, 2021
See what ranked most popular in our top 10 stories of 2020.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Blogs
The MGD patient journey: maintenance over time
January 21, 2021
Cynthia Matossian, MD, FACS, ABES, continues her discussion on MGD treatment by explaining why it's important for patients to understand that MGD and dry eye are lifelong, chronic conditions requiring regular maintenance and monitoring.
The MGD patient journey: diagnosis + initial treatment
January 09, 2021
Cynthia Matossian, MD, FACS, ABES, discusses the big disconnect between signs and symptoms of ocular surface disease, including meibomian gland dysfunction, and why a clear process for educating patients and initiating treatment is essential.
Oh, the people we meet
December 21, 2020
Chief Medical Editor Peter McDonnell, MD, explains why the individuals that we make an impact on as physicians often never forget us.
Dr. Mali's top 5 predictions for ophthalmology in 2021
December 19, 2020
In light of an unprecedented year filled with technological advancements and pivots, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2021.
Dr. Mali: Top 5 predictions for ophthalmology in 2021
December 19, 2020
Joshua Mali, MD, speaks on his annual top 5 predictions in ophthalmology for what's to come in 2021.
Planning is important — even when “nobody knows nothing”
December 03, 2020
A word from Chief Medical Editor Peter J. McDonnell, MD.
Where to start with treating OSD patients
October 17, 2020
Cynthia Matossian, MD, FACS, advises on how ophthalmologists can start performing a better diagnosis of ocular surface disease in three simple steps.
When at first you don’t succeed with MGD patients, keep trying
September 23, 2020
It's not always easy to convince early-stage, minimally symptomatic or symptomatic patients that their MGD should be treated. Cynthia Matossian, MD, FACS, explains why ophthalmologists shouldn't take this personally and how not to accept their denial as a final answer.
As cyclosporine options grow, focus remains on the vehicle
September 10, 2020
Amid a surge in dry eye cases since reopening her practice during the ongoing pandemic, Lisa Nijm, MD, JD, shares how cyclosporine, a well-established form of treatment, poses both challenges and advantages for ophthalmologists.